PharmaThene receives payment from Biomedical Advance Research and Development Authority

PharmaThene is the distributor of the SparVax anthrax vaccine.
PharmaThene Inc. recently announced that it has received a $5.8 million payment from Biomedical Advance Research and Development Authority (BARDA), as reconciliation between actual and provisional rates on the performance of the SparVax (an anthrax vaccine) contract for years 2008 to 2013 and actual costs that accrued during that period.

The contract expired Feb. 28.

Future government funding to support the development of SparVax is unlikely, PharmaThene officials said.

"Even if we received such funding, significant additional non-clinical animal studies, human clinical trials and manufacturing development work remain to be completed for all of our product candidates," a statement from PharmaThene said. "It is also uncertain whether any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans."

Copies of PharmAthene's public disclosure filings are available at www.PharmAthene.com.